Related Experiment Video

Updated: May 23, 2026

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein
11:23

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein

Published on: June 30, 2019

LIMK2 is a crucial regulator and effector of Aurora-A-kinase-mediated malignancy

Emmanuel O Johnson1, Kuei-Hua Chang, Soumitra Ghosh

  • 1Department of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, IN 47907, USA.

Journal of Cell Science
|April 12, 2012
PubMed

Insights

Researchers identified LIMK2 as a novel Aurora A substrate, crucial for breast cancer progression. Targeting LIMK2 offers a new strategy for cancer therapy by disrupting Aurora A

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Aurora A kinase is frequently overexpressed in breast cancer, driving oncogenic pathways.
  • Known Aurora A substrates with oncogenic roles in breast cancer are limited, highlighting a need for new target identification.

Purpose of the Study:

  • To identify novel oncogenic Aurora A substrates in breast cancer using a chemical genetic approach.
  • To elucidate the regulatory relationship between Aurora A and its newly identified substrate, LIMK2.

Main Methods:

  • Utilized a chemical genetic screen to identify Aurora A targets.
  • Investigated the phosphorylation of LIMK2 by Aurora A at specific sites (S283, T494, T505).
  • Assessed the impact of LIMK2 ablation on Aurora A-mediated tumorigenesis in vivo and in vitro.

Main Results:

  • Identified LIM domain-containing protein kinase 2 (LIMK2) as a novel substrate of Aurora A.
  • Demonstrated that Aurora A directly phosphorylates LIMK2, regulating its activity, localization, and protein levels.
  • Established a positive-feedback loop where LIMK2 upregulates Aurora A, amplifying oncogenic signaling.
  • Showed that LIMK2 ablation completely prevents Aurora A-driven tumorigenesis in mice.
  • Found synergistic cell death induction when combining LIMK2 ablation with Aurora A inhibition.

Conclusions:

  • LIMK2 is a key oncogenic effector of Aurora A in breast cancer, forming a critical positive-feedback loop.
  • Targeting LIMK2, through inhibition or ablation, represents a promising therapeutic strategy for cancers with Aurora A deregulation.
  • The Aurora A-LIMK2 axis is a conserved mechanism across multiple cancer types, suggesting broad therapeutic potential.

More Related Videos

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...